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Title: Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor neurone disease 
 
Highlights 
1. What is already known about this topic? 
The Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) is the preferred 
measure of health outcome in clinical trials of interventions in motor neurone disease. 
Preference-based measures are rarely used within the field of motor neurone disease. 
 
2. What does the paper add to existing knowledge? 
The mapping provides an algorithm to link a validated and commonly used measure of health 
outcome in motor neurone disease to the EuroQoL EQ-5D-5L.  
This allows for health utilities to be estimated for cost-effectiveness analyses, based on responses to 
the ALSFRS-R. 
 
3. What insights does the paper provide for informing health care-related decision making? 
The ALSFRS-R can be used to estimate EQ-5D-5L utilities when they have not been collected 







Background: The Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) is 
the preferred measure of health outcome in clinical trials in motor neurone disease (MND). 
However it does not provide a preference-based health utility score, required for estimating QALYs 
in economic evaluations for health technology assessments.  
Methods: Direct mapping models were developed using Ordinary Least Squares (OLS) and Tobit 
regression analyses to estimate EQ-5D-5L utilities (based on English tariffs) with ALSFRS-R total, 
domain and item scores used as explanatory variables, using patient-level data from a UK cohort 
study. Indirect mapping models were also used to map EQ-5D-5L domains, using the same 
variables, along with the Neuropathic Pain Scale (NPS) and Hospital and Anxiety Depression Scale 
for MND (MND-HADS) using multinomial logistic regression analysis. Goodness-of-fit was 
assessed along with predicted values for each mapping model.  
Results: The best performing model predicting EQ-5D-5L utilities used 5 items of the ALSFRS-R 
items as explanatory variables in a stepwise OLS regression. The mean squared error was 0.0228, 
and the absolute mean error was 0.1173. Prediction was good, with 55.4% of estimated values 
within 0.1 and 91.4% within 0.25 of the observed EQ-5D-5L utility value. Indirect mapping using 
the NPS and HADS provided less predictive power than direct mapping models.  
Conclusion: This is the first study to present mapping algorithms to ’crosswalk’ between ALSFRS-
R and EQ-5D-5L. This analysis demonstrates that the ALSFRS-R can be used to estimate EQ-5D-






1. Introduction  
Motor Neurone Disease (MND) (also known as Amyotrophic Lateral Sclerosis, ALS) is a 
progressively degenerative neurological condition, which affects the motor neurones in the brain 
and spinal cord. Life expectancy is between 3 to 5 years from symptom onset [1] and quality of life 
(QoL) is greatly impaired. Established treatments are symptom management, riluzole which 
increases median survival by about 3 months [2], and palliative care [3].  
The recent approval of edaravone [4] by the US Food and Drug Administration (FDA) and the 
development of other new treatments options [5,6] will increase the need for evidence to support 
health technology assessment (HTA) and reimbursement decisions. At present, there is limited 
literature on preference-based health utilities in patients with MND [7], which are required for the 
calculation of quality-adjusted life-years (QALYs) for cost-utility analyses. 
The EuroQoL EQ-5D is the preferred measure of the National Institute for Health and Care 
Excellence (NICE) [8] for calculating QALYs and the most widely used generic preference-based 
health outcomes measure, facilitating comparisons of health technologies between different diseases 
[9]. However, concerns have been expressed in applying this measure to MND patients, as it does 
not account for a range of symptoms, including communication, fatigue, swallowing and respiratory 
difficulty [1]. Previous experience of the EQ-5D-3L version in patients with MND, is that the 
measure can be used but with cautions of ceiling/floor effects, amongst other issues [10,11]. 
When EQ-5D data are not available, NICE allows for utilities be estimated by mapping from other 
health-related QoL measures [12]. A number of studies concerned with mapping disease-specific 
QoL instruments to the EQ-5D have been published [8,13] and guidelines produced for best 
practice [14,15]. Mapping from a non-preference based measure to the EQ-5D can be performed by 
predicting either the EQ-5D health utility values (direct mapping) or each of the five domain 
responses (indirect mapping). However, there is limited use of either approach in the context of 





The Amyotrophic Lateral Sclerosis Functioning Rating Scale-Revised (ALSFRS-R) [18] is 
recommended for use in clinical trials of treatments for MND [19] to capture clinical changes in 
areas of motor, bulbar and respiratory function. While this is not a preference-based measure, the 
ALS Utility Index, which is derived from 5 items of the ALSFRS-R and based on US general 
population tariff scores, does allow for utilities to be estimated [20], but has not been used in MND 
patients.  
The aim of our study is to develop algorithms for mapping, both directly and indirectly, from 
measures used in MND clinical studies to allow for future prediction of EQ-5D-5L utility in 
populations of MND patients where utility data have not been collected. 
2. Methods  
2.1 Data  
Data were sourced from the on-going Trajectories of Outcomes in Neurological Conditions 
(TONiC) study [21]. This longitudinal study of QoL and economic outcomes includes a large 
cohort of patients with MND recruited throughout the UK. Participants complete a series of 
outcome measures and provide demographic and clinical information. 
For the analysis, we used baseline responses from a cross-section of patients recruited by MND 
clinical and research teams up to January 2017, who were at different stages of the disease course. 
Cross-sectional rather than longitudinal data were used as only 106 from 636 patients had returned 
any follow-up questionnaires at the time of analysis for this paper. All questionnaires used in the 
mapping analysis were returned in a single pack which the participant was requested to complete on 
the same day if possible. Clinicians allocated MND to limb, bulbar or respiratory onset types and 
performed disability assessment using the ALSFRS-R. 
Ethical approval was granted from NRES Committee North West - Greater Manchester West 





2.2 Missing data 
Mapping was only conducted for participants for whom complete data were available.  A logistic 
regression was used to test whether participants who had returned incomplete questionnaires were 
comparable to those who had fully completed questionnaires, in terms of their age, gender, MND 
onset type, independent completion of questionnaires and recruiting centre. 
2.3 Measures  
The EQ-5D-5L was included in the TONiC study to estimate health utilities. It covers the health 
domains of mobility, self-care, usual activities, pain and anxiety/depression, each with five levels of 
severity [22]. A preference-based single index score can be generated with any combination of 
responses, anchored at 0 to represent death, 1 representing full health and, based on an English 
tariff, includes the worst health state of -0.281. These health utility values have been developed 
using general public responses to a standard gamble survey. 
Three measures were selected from the TONiC dataset for the purposes of mapping to EQ-5D-5L: 
1) ALSFRS-R, from which the ALS Utility Index was derived 
The revised version of the ALSFRS incorporates respiratory items, increasing the sensitivity of the 
instrument to changes in the disease course of MND [18]. The ALSFRS-R is a validated MND-
specific 12-item questionnaire, concerning bulbar, limb and respiratory function. Responses range 
from a score of 0 (severe problems) to 4 (no change). Responses to the ALSFRS-R are often used to 
derive a single index value and this value is reported in many clinical studies, but recent evidence 
suggests that the ALSFRS-R should be examined on a domain level, to generate either 3 or 4 
domain scores to overcome concerns of unidimensionality [23] (Figure 1). 
Insert Figure 1 here 
The ALS Utility Index is derived from the following ALSFRS-R domains: speech and swallowing, 





from members of the general public in the US using the standard gamble method and can be used to 
calculate a single preference-based utility score for persons with MND. 
2) Neuropathic Pain Scale (NPS)  
The Neuropathic Pain Scale [24] measures the intensity, unpleasantness and sharpness of 
neuropathic pain. The questionnaire consists of 10 scales with varying descriptions of pain, each 
with a possible response value between 0 (no pain) and 10 (worst pain imaginable).  A further item 
concerns the length of time the patient has experienced pain with a score of between 0 and 2. 
Responses to the scales and the time item are summed to provide an NPS index score.  
3) Hospital and Anxiety Depression Scale for MND (MND-HADS)   
The MND-HADS [25] is a modified version of the Hospital and Anxiety Depression Scale (HADS) 
[26], developed for use in MND populations to address concerns that items in the original HADS 
may be confounded by physical disability. The modified HADS-A and HADS-D, which have 
acceptable psychometric properties, resulted from the removal of one item from both 7-item scales. 
2.4 Statistical methods   
With our aim of developing a crosswalk between the selected measures available in the TONiC 
study and the EuroQoL EQ-5D-5L, we tested a variety of model types and structures to arrive at a 
preferred model, and present alternative acceptable models that may suit different scenarios 
depending on data availability. Models based on direct mapping to EQ-5D-5L utilities (based on the 
English tariff [22]) and indirect mapping to EQ-5D-5L domains were tested. We randomly divided 
our dataset into estimation and validation samples in a 2:1 ratio, allowing algorithms generated in 
the estimation sample to predict values in the validation sample.  
For the direct mapping analysis, we considered the ALSFRS-R by individual items, 3 and 4 
domains variables and index score (Table 1; Figure 1). Individual item responses to the ALSFRS-R 





on distinctive features of MND [23], and the index score was selected based on it being reported in 
many clinical studies in MND. The ALSUI was analysed by index score only as this measure is 
preference-based and therefore the index value combined weighted domain responses.  
Two model types were chosen for the direct mapping.  Firstly, we used ordinary least squares 
(OLS) regression which has been used extensively in comparable studies with acceptable 
performance [13]. Given that EQ-5D-5L utility data are skewed, however, violating the assumption 
of normality, and are censored at the upper limit of 1, we also used a Tobit regression model [27], 
and compared the results with OLS regressions models. 
For all indirect mapping analyses, we used multinomial logistic regression to account for the 
categorical nature of EQ-5D domains, and the ordering of EQ-5D domain levels (Table 1). Initially, 
we used the same combinations of explanatory variables as in our direct mapping analysis. We then 
undertook a second indirect mapping analysis, which included the additional measures of the NPS 
and MND-HADS. These were included to overcome the lack of pain and mental health domains 
within the ALSFRS-R, therefore aiding our indirect mapping analysis. All models, direct and 
indirect, were run with and without the demographic variables of age, gender and MND onset type. 
All regression analyses were performed on the estimation sample, with generated results used to 
predict values using the validation sample. Furthermore a stepwise selection was used to examine if 
a reduced ALSFRS-R item model was more appropriate, in regards to removing variables whose 
coefficients were not rationally directed, and to test if a more efficient model could be obtained.  
Data management was carried out using Microsoft Excel (Microsoft, Washington, USA) and R 
statistical software version 3.0 (Vienna, Austria) [28] was used for statistical analysis.  
2.5 Assessing Model Performance  
Model performance was examined by the mean squared errors (MSE) and mean absolute errors 
(MAE), in line with mapping guidance [8,14], to identify the best predictive models. For optimal 





complement the MSE analysis and ensure that models selected based on a lower MSE score also 
had a lower MAE score. 
Tests of systematic bias in selected models, chosen by lowest MSE score, were performed by 
examining the percentage of predicted values which deviated from observed values by more than 
0.10 and 0.25. In order to identify if the selected models performed better for particular ranges of 
utility values, we also present the errors for the following categories of EQ-5D-5L utility scores: <0, 
0 to <0.2, 0.2 to <0.4, 0.4 to <0.6, 0.6 to <0.8, 0.8 to 1. The plotting of histograms of the residuals 
of observed and predicted values of the selected model provided visual evidence of the nature of 
errors present in the models. Examination of mean differences in utility values between data sets 
was also undertaken. Finally, the Akaike Information Criterion (AIC) [29] was used to test the fit of 
models with lowest MSE for each of the explanatory variable groups in the direct mapping and also 
for all indirect mapping models. 
The conduct and reporting followed guidance from the MApping onto Preference-based measures 
reporting Standards (MAPS) statement [14].    
3. Results  
3.1 Data Characteristics 
Questionnaires were posted to 958 patients. A response rate of 66.4% for our cross-sectional data 
set was achieved, resulting in 636 returned questionnaires. 41 were incomplete for direct mapping, 
leaving a total of 595 completed patient questionnaires for inclusion in this analysis.  Respondents 
who did not fully complete questionnaires were not statistically different from those who returned 
completed questionnaires, with respect to the variables tested (supplementary appendix). For the 
direct mapping, 397 patients were randomly assigned to the estimation sample and 198 to the 
validation sample. For indirect mapping, 18 patients had not completed the required additional 
questionnaires, therefore 385 patients were in the estimation sample and 192 in the validation 





onset type (bulbar, limb and respiratory), severity of EQ-5D domain responses, their EQ-5D-5L and 
ALSUI utility values, and ALSFRS-R, NPS and MND-HADS scores (Tables 2 and 3). The mean 
age of respondents was 65.1 years, which is in line with reported average ages of MND patients, 
while the gender split of 61% male is also reflected within the literature [30]. 
Figure 2 shows the distributions of the EQ-5D-5L utilities, ALSFRS-R index values and ALSUI 
scores in both samples. The number of individuals reporting negative EQ-5D-5L in our full dataset 
was 13 (2.2%). EQ-5D-5L utility ranged from -0.21 to 1, whereas the ranges of other measures 
were: ALSFRS-R (1 to 48), ALSUI (0 to 1), NPS (0 to 85) and MND-HADS (0 to 28). 
Insert Figure 2 here 
The distributions of responses varied across the EQ-5D domains (Table 3), with mobility and usual 
activities associated with greater proportions of severe problems, compared to other domains, 
reflecting the impact of MND upon patients’ motor functioning. There were fewer responses in the 
more severe categories of pain/discomfort, with 5 (0.8%), and anxiety/depression with 6 (1.0%) 
individuals reporting severe problems.  
3.2 Model Performance 
The results of our mapping analysis by model type are presented in Table 4. Patient demographics 
were significant predictors of EQ-5D-5L utilities in only model OLS 1b; results for the other 
models with demographic variables are therefore not presented.  
Direct mapping 
Direct mapping models were compared in terms of their fitted values deviating by more than 0.1 
and 0.25 of the true utility. This ranged from 31.3% to 55.4% for within 0.10 of true value; and 
56.3% and 91.4% within 0.25. Direct mapping models generally performed well in estimating mean 
utility in the estimation sample, with all models predicting the mean correctly to 2 decimal places.  





places, and only three predicted negative utility values. Model OLS (5) demonstrated the lowest 
MSE (0.0245), MAE (0.1218) and AIC values in the validation sample; however it contained non-
significant coefficients, and negative (counterintuitive) coefficients on items 1 to 4, and 12. For 
these reasons, among direct mapping models the use of the reduced ALSFRS-R item model with 
stepwise selection of explanatory variables (model OLS (6)) is preferred.  While MSE (0.0228), 
MAE (0.1173) and AIC all indicated model OLS (6) to provide the best fit of the data, the predicted 
errors were not uniform across the range of EQ-5D-5L utility scores (Table 5).  Larger errors were 
apparent for negative utilities and for utilities in the range of 0 to 0.2. Figure 3 presents the fitted 
versus observed values, and Figure 4 plots the residuals. The model was strongest when predicting 
values from 0.2 to 0.8. 91.7% of estimations were within 0.25 of the observed EQ-5D-5L values, 
with 55.4% within 0.10 of the true value. The algorithm generated from this regression is presented 
below: 
EQ-5D-5L utility = 0.086203 + 0.057486*item6 + 0.046674*item7 + 0.058688*item8 + 
0.035927*item9 + 0.021126*item10s 
Insert Figures 3 and 4 here 
Indirect mapping 
All indirect mapping models using the ALSFRS-R or ALSUI were upwardly biased as they 
consistently predicted higher utility values. They reported higher MSEs and MAEs than the direct 
mapping models using the same clinical information, but while the use of the additional measures of 
the NPS and MND-HADS resulted in lower errors, these models did not outperform direct mapping 
models.  
To researchers who may benefit from our mapping analysis, and recognising that data availability 
may differ from one study to another, we present the complete results of the best performing models 





4. Discussion  
Our study provides evidence that the ALSFRS-R, conceptually, could be a good candidate for 
mapping to the EQ-5D-5L in MND patients as the domain themes which appear in the EQ-5D (pain 
and anxiety/depression) but not in the ALSFRS-R, are reported in less severe terms in MND 
patients. This may partially explain why our mapping results fell within the reported MSE ranges of 
other mapping studies [13],and allowed us to assert that mapping from the ALSFRS-R to the EQ-
5D-5L is viable. 
The various ALSFRS-R mapping models showed markedly better predictive results than the models 
using the ALSUI when estimating EQ-5D-5L utilities. This may be in part due to the use of US 
preference tariff in the ALSUI, contrasting with our use of the English EQ-5D-5L tariff given the 
population from which the data were derived; but also the different selection of ALSFRS-R 
domains in their construct. The ALSUI estimated utility from items 1, 6, 8, 10 and 12 of the 
ALSFRS-R, whereas our best fitting model, OLS (6) used items 6 to 10.  More research is needed 
to confirm the external validity of the ALSUI, and the extent to which it can be used to complement 
generic preference-based measures. Based on our mapping analysis, we cannot recommend using 
this measure to crosswalk to the EQ-5D-5L in MND patients.  
As with the majority of previous mapping studies, our analysis found OLS regressions to have the 
strongest predictive power, slightly bettering the results from the Tobit regressions for direct 
mapping [13]. Indirect mapping models with the same specifications as the direct models showed 
higher MSEs using a multinomial logistic regression and consistently estimated larger mean EQ-5D 
utilities compared to observed values. The addition of the NPS and HADS to the indirect models 
reduced reported MSEs, but not to the extent as estimated in the direct mapping models. 
Demographic information did not significantly improve predictive power of the models, with the 





Our preferred model OLS (6), using a selection of ALSFRS-R items as explanatory variables, had 
MSE and MAE values comparable to other neurological statistical mapping work [16,17], and to 
errors reported in mapping studies in general [13]. The fact that our most accurate model, in terms 
of lowest MSE, contained only 5 items from the 12 item ALSFRS-R highlights the limitations of 
the use of the EQ-5D-5L within MND populations. There are characteristics of the disease, as 
defined by the main disease-specific measure in MND, that do not influence the metric of EQ-5D-
5L health utility. These are: communication, salivation, swallowing, hand use, and respiratory 
function.  
This study is a useful addition to the literature, in that it presents results for both direct and indirect 
mapping algorithms, using a variety of model structures. Few previous mapping studies have 
carried out both approaches on the same dataset [13]. Ours is the first study, to our knowledge, to 
have carried out such an analysis within an MND population, and provides useful evidence for the 
development of economic analyses in MND where EQ-5D data have not been collected directly. A 
strength of the analysis was the completeness of returned questionnaires with no evidence that data 
were not missing at random. 
Our analysis may have been more robust, however, if we had access to data for a greater number of 
patients. In being a longitudinal study, TONiC offered the opportunity for an analysis of repeated 
measures to increase the power of the study, but as only 106 (of 636 patients) had returned at least 1 
follow-up questionnaire pack at our cut-off date, we considered this to be an insufficiently 
representative sample for such an analysis. TONiC nonetheless represents both the largest and one 
of the most detailed quality of life studies for MND in the world. The strongest models within this 
study were unable to predict negative utility values for patients with MND, and had a higher error 
rate for low utility scores. This is of concern as MND is associated with relatively low utility values 
reflecting very poor health-related quality of life, although our data had only a few patients 





from a sample of data which stems from the same study. While this is commonplace in the literature 
[13-15], external validation would have been preferable in the context of assessing broader 
generalisability. Finally, it should be noted that directly collected data on EQ-5D-5L utilities always 
supersedes predicted values based on mapping algorithms.     
5. Conclusion  
Many studies in MND have not used preference-based utility measures, which are required 
increasingly to support health technology assessment and reimbursement decisions. The algorithms 
presented here provide an option for estimating EQ-5D-5L utility when this has not been collected 
directly from MND patients. This study has shown that it is possible to predict, with reasonable 
accuracy (based on reported MSE ranges for other mapping studies), EQ-5D-5L utility values from 
the ALSFRS-R. It is also possible to map indirectly to EQ-5D-5L domains if the NPS and MND-
HADS have been used alongside the ALSFRS-R. These findings should aid health technology 
assessment of interventions for MND, by providing evidence linking commonly used clinical 
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Table 1: Mapping models used in statistical analysis  
Model number  Explanatory variables Statistical methods 
Direct Mapping 
1a ALSFRS-R Index  OLS and Tobit 
1b ALSFRS-R Index and demographics OLS and Tobit  
2 ALSFRS-R 4 Domains  OLS and Tobit  
3 ALSFRS-R 3 Domains  OLS and Tobit  
4 ALS Utility Index OLS and Tobit 
5 ALSFRS-R items OLS and Tobit 
6 Stepwise ALSFRS-R items OLS and Tobit 
Indirect mapping 
7 ALSFRS-R Index  Multinomial 
Logistic  
8 ALSFRS-R 4 Domains  Multinomial 
Logistic  
9 ALSFRS-R 3 Domains  Multinomial 
Logistic  
10 ALS Utility Index Multinomial 
Logistic  
11 ALSFRS-R items Multinomial 
Logistic  
12 Stepwise ALSFRS-R items Multinomial 
Logistic  
13 ALSFRS-R index score, NPS and MND-HADS Multinomial 
Logistic  
14 ALSFRS-R 4 domains, NPS and MND-HADS Multinomial 
Logistic 
15 ALSFRS-R 3 domains, NPS and MND-HADS Multinomial 
Logistic  
16 ALSUI score, NPS and MND-HADS Multinomial 
Logistic  
17 ALSFRS-R items, NPS and MND-HADS Multinomial 
Logistic  









Table 2 – Patient characteristics  






Demographics    
Male n (%) 363 (61.0)                          243 (61.2)   120 (60.6) 
Age mean (SD) 65.07 (10.89)  65.25 (10.89) 64.70 (10.6) 
    
MND Onset n (%)    
Limb  404 (69.9) 265 (66.8) 139 (70.2) 
Bulbar n (%) 159 (26.7)  112 (28.2)  48 (26.7) 
Respiratory n (%) 11 (2.5)  8 (2.0)  3 (2.5) 
    
Measures mean (SD)    
EQ-5D-5L index  0.57 (0.26)  0.57 (0.26)  0.58 (0.27) 
EQ-5D VAS  0.60 (21.30)  0.61 (22.01)  0.60 (21.78) 
ALSFRS-R score 31.95 (8.33)  31.85 (8.13) 32.15 (8.73) 
ALS Utility Index 0.40 (0.24)  0.40 (0.24)  0.41 (0.24) 
Neuropathic Pain Scale  30.02 (16.40) 28.74 (16.95)  32.62 (15.01) 






Table 3 – Distribution of responses by EQ-5D-5L domains  




Validation Sample  
(n=198)  
Mobility  n (%) n (%) n (%) 
Level 1 99 (16.6) 63 (15.9) 36 (18.2) 
Level 2 81 (13.2) 54 (13.6) 27 (17.6) 
Level 3 157 (26.4) 106 (26.4) 52 (26.3) 
Level 4  152 (25.6) 100 (25.2) 52 (26.3) 
Level 5 106 (17.8) 75 (18.9) 31 (15.7) 
Self-care    
Level 1 118 (19.8) 85 (21.4) 33 (16.7) 
Level 2 152 (25.6) 88 (22.2) 64 (32.3) 
Level 3 162 (27.2) 110 (27.7) 52 (26.3) 
Level 4 71 (11.9) 52 (13.1) 19 (9.6) 
Level 5 92 (15.5) 62 (15.6) 30 (15.2) 
Usual Activities     
Level 1 53 (8.9) 35 (8.8) 18 (9.1) 
Level 2 117 (19.7) 71 (17.9) 46 (23.2) 
Level 3 174 (29.2)  118 (29.7)  56 (28.3) 
Level 4 118 (19.8) 85 (21.4) 33 (16.7) 
Level 5 115 (22.4) 88 (22.2) 45 (27.7) 
Pain/discomfort    
Level 1 179 (30.1) 116 (29.2) 63 (31.8) 
Level 2 213 (33.8) 140 (35.3) 73 (36.9) 
Level 3 161 (27.1) 114 (28.7) 47 (23.7) 
Level 4 37 (3.6) 22 (5.5) 15 (7.6) 
Level 5 5 (0.8) 5 (1.3) 0 (0.0) 
Anxiety/depression     
Level 1 268 (45.1) 181 (45.6) 87 (43.9) 
Level 2 203 (34.1) 131 (33.0) 72 (36.4) 
Level 3 98 (16.5) 66 (16.6) 32 (16.2) 
Level 4 20 (3.3) 15 (3.8) 5 (2.3) 





Table 4 – Mapping results  
Model  Estimation Sample (n=397) Validation Sample (n=198) 




0.57 (0.26) -0.2, 1 N/A N/A 0.58 (0.26) -0.21, 1 N/A N/A 
Direct Models         
OLS (1) 0.57 (0.19)      0.1, 0.86    0.0404   0.1594 0.57 (0.18)   -0.06, 0.9             0.037    0.1552 
OLS (1b) 0.57 (0.19)      0.04, 1 0.0339 0.1448 0.57 (0.19) -0.06, 1 0.0306 0.1407 
OLS (2) 0.57 (0.21)     0.08, 0.96 0.0239 0.1202 0.57 (0.15) 0.1, 0.96 0.0461 0.1794 
OLS (3) 0.57 (0.20) 0.05, 0.94 0.0447 0.1245 0.57 (0.15) 0.08, 0.94 0.0281 0.1306 
OLS (4) 0.57 (0.16)     0.03, 0.92 0.0219 0.1201 0.57 (0.16) 0.3, 0.95 0.0441 0.1731 
OLS (5) 0.57 (0.22)     0.09, 0.98 0.0224 0.1135 0.57 (0.22) 0.1, 0.98 0.0245 0.1218 
OLS (6) 0.57 (0.21)     0.09, 0.96  0.0221 0.1112 0.58 (0.21) 0.1, 0.97 0.0228 0.1173 
Tobit (1) 0.57 (0.17)     0.09, 0.87 0.0405 0.1589 0.59 (0.18) -0.06, 0.91 0.0371 0.1545 
Tobit (1b) 0.57 (0.19) 0.05,0.99 0.0356 0.1453 0.57 (0.20) -0.01,0.92 0.0310 0.1423 
Tobit (2) 0.57 (0.17)     0.07, 0.85 0.0421 0.1625 0.51 (0.15) 0.03, 0.81  0.0466 0.1801 
Tobit (3) 0.57 (0.21)     0.03, 0.97 0.0271 0.1283 0.55 (0.20) 0.01, 0.92 0.0280 0.1329 
Tobit (4) 0.57 (0.16)     0.3, 0.93 0.0447 0.1711 0.58 (0.16) 0.3, 0.97 0.0442 0.1730 
Tobit (5) 0.57 (0.22)      0.08, 1 0.0219 0.1132 0.57 (0.22) 0.09, 0.99 0.0255 0.1288 
Tobit (6) 0.57 (0.21)     0.08, 0.9 0.0233 0.1149 0.57 (0.21) 0.09, 0.98 0.0250 0.1241 
         
Indirect 
Models 
        
Mlogit (7) 0.65 (0.24)     0.17, 0.95 0.5660 0.1794 0.66 (0.23) 0.17, 1 0.0597 0.1812 
Mlogit (8) 0.66 (0.22)     0.17, 1 0.0390 0.1285 0.67 (0.58) 0.17, 1 0.0320 0.1415 
Mlogit (9) 0.64 (0.24)     0.17, 1 0.0360 0.1379 0.60 (0.25) -0.02, 1 0.0303 0.1342 
Mlogit (10) 0.61 (0.23)     0.17, 1 0.0501 0.1811 0.62 (0.22) 0.17, 0.95 0.0510 0.1732 
Mlogit (11) 0.62 (0.21)     0.01, 0.95 0.0274 0.1165 0.62 (0.22) -0.02, 1 0.0315 0.1526 





Mlogit (13) 0.57 (0.22)     -0.07, 1 0.0199 0.1034 0.58 (0.22) -0.02, 1 0.0308 0.1310 
Mlogit (14) 0.72 (0.23) 0.34,1 0.0989 0.2421 0.58 (0.21) 0.17,1 0.0534 0.2181 
Mlogit (14) 0.74 (0.22)      0.49, 0.93 0.0954 0.2339 0.60 (0.21) 0.34, 0.94 0.0663 0.2316 
Mlogit (15) 0.59 (0.23)      0.09, 1 0.1581 0.1581 0.59 (0.22) -0.02, 1  0.0497 0.1757 
Mlogit (16) 0.49 (0.22)     -0.09, 1 0.1870 0.1870 0.51 (0.11) 0.51, 1 0.0657 0.1956 
Mlogit (17) 0.59 (0.22)     -0.1, 1 0.2010 0.2010 0.59 (0.21)    0.17, 1 0.0441 0.2301 
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